Keratoconus and Ectasia Treatment Plan (Compassionate)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Keratoconus and pellucid marginal degenerations are genetically based ocular conditions and post surgical ectasia is an iatrogenic condition. These diseases are characterized by weakening of the front part of the eye that causes thinning and distortion. This distortion results in unevenness of the cornea and produces progressive near-sightedness and irregularity, which causes loss of vision when using eyeglasses. When eyeglasses fail to give enough vision, the the investigators use rigid contact lenses to create an artificial front eye surface. This improves visual acuity in many patients although they eventually fail either because they cannot be tolerated or the surface irregularity has become so severe that they are rejected. At this stage there is usually thinning and loss of clarity of the eye.
There has been no treatment for this other than corneal transplantation, a complex surgical procedure with a significant complication rate and a delay in visual recovery. The treatment the investigators wish to perform strengthens the front of the eye by a chemical reaction using light and riboflavin. This technique has been studied over a decade and is widely used throughout the world. The FDA approved multicenter American clinical study is being analyzed in anticipation of its submission to the FDA for PreMarket approval. Because this is a progressive condition, the investigators wish to be able to offer this on a limited basis to patients in need with vision loss.
Any treatment that can delay or prevent corneal transplantation is of great benefit. The investigators believe the evidence is compelling that this treatment is the sole alternative to surgical transplantation.
| Condition | Intervention |
|---|---|
|
Keratoconus Ectasia |
Other: Riboflavin Solution Device: UV-X Illumination System |
| Study Type: | Expanded Access What is Expanded Access? |
| Official Title: | Increasing CrossLinking of Corneal Collagen in Eyes With Progressive Keratoconus or Ectasia |
| Study Start Date: | September 2010 |
| Estimated Study Completion Date: | April 2012 |
| Estimated Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
-
Other: Riboflavin Solution
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Subjects who have one or both eyes that meet all of the following criteria will be considered candidates for this treatment:
For Keratoconus and Ectasia:
- 18 years of age or older
Having a diagnosis of progressive keratoconus defined as one or more of the following changes over a period of 24 months or less before randomization:
- An increase of >; 1.00 D in the steepest keratometry value (or sim K)
- An increase of >; 1.00 D in regular astigmatism evaluated by subjective manifest refraction
- A myopic shift (decrease in the spherical equivalent) of > 0.50 D on subjective manifest refraction
- Documented decrease in visual acuity associated with irregular astigmatism and topographic features of ectasia.
- Presence of central or inferior steepening on the Pentacam map.
- Axial topography consistent with keratoconus
Presence of one or more slit lamp findings associated with keratoconus, such as:
- Fleischer ring
- Vogt striae
- Corneal thinning
- Corneal scarring
Contact Lens Wearers Only:
- Removal of contact lenses are required prior to the screening-Contact Lens 7. Signed written informed consent
Exclusion Criteria:
All subjects meeting any of the following criteria will be excluded from this treatment:
- No evidence of progression.
- Excessively thin corneas.
Previous ocular condition in the eyes to be treated that may predispose the eye for future complications, for example:
- History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.)
- Clinically significant corneal scarring in the proposed treatment zone
- A history of chemical injury or delayed epithelial healing in the eye(s) to be treated.
- A known sensitivity to treatment medications
- Patients with a current condition that, in the treating physician's opinion, would interfere with or prolong epithelial healing.
Contacts and Locations| Contact: MaEdylin Bautista, MD | 212.305.5922 | mmb2225@columbia.edu |
| United States, New York | |
| Edward Harkness Eye Institute-Columbia University Medical Center | |
| New York, New York, United States, 10032 | |
| Contact: MaEdylin Bautista, MD 212-305-5922 mmb2225@columbia.edu | |
| Principal Investigator: Stephen Trokel, MD | |
| Principal Investigator: | Stephen L Trokel, MD | Columbia University, Department of Ophthalmology, College of Physicians and Surgeons |
More Information
Publications:
| Responsible Party: | Stephen Trokel, Professor of Clinical Ophthalmology, Columbia University |
| ClinicalTrials.gov Identifier: | NCT01384773 History of Changes |
| Other Study ID Numbers: | AAAF0594 |
| Study First Received: | June 27, 2011 |
| Last Updated: | November 20, 2012 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board |
Keywords provided by Columbia University:
|
Keratoconus Ectasia UVA light riboflavin |
post-LASIK (laser in situ keratomileusis) pellucid marginal degeneration irregular astigmatism |
Additional relevant MeSH terms:
|
Dilatation, Pathologic Keratoconus Pathological Conditions, Anatomical Corneal Diseases Eye Diseases Riboflavin Photosensitizing Agents Radiation-Sensitizing Agents |
Physiological Effects of Drugs Pharmacologic Actions Dermatologic Agents Therapeutic Uses Vitamin B Complex Vitamins Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on June 13, 2013